ISAL 2017 | Are IDH mutations good minimal residual disease (MRD) markers in acute myeloid leukemia (AML)?
Felicitas Thol, MD, from Hannover Medical School, Hannover, Germany, discusses whether IDH1 and IDH2 mutations are good markers for minimal residual disease (MRD) in acute myeloid leukemia (AML) at the International Symposium on Acute Leukemias (ISAL) 2017 in Munich, Germany. She explains that there are some good MRD markers, such as NPM1. However, for IDH1 and IDH2, there is evidence that they occur early in clonal evolution and may therefore not be good markers for MRD. In addition, she describes how IDH1 and IDH2 can still be present with a high mutational load in patient who are in complete remission (CR), with no clear correlation between the proportion of blasts and the mutation load. Dr Thol concludes that IDH1 and IDH2 are probably not good markers for monitoring minimal residual disease.
